Bisphosphonates are effective prophylactic of early bone loss after renal transplantation

Transplant Proc. Jan-Feb 2006;38(1):165-7. doi: 10.1016/j.transproceed.2005.12.041.

Abstract

Introduction: Rapid bone loss and fractures occur early after solid organ transplantation. We examined the preliminary results of a prospective study evaluating the efficacy of prophylactic use of bisphosphonates in renal allograft recipients.

Methods: Bone mineral density (BMD) was measured at the lumbar spine and the hip by dual energy X-ray absorptiometry at 1, 6, 12 months. Alendronian or risedronian were initiated for patients with osteopenia or osteoporosis at 1 month who had no contraindications to bisphosphonates. The treatment lasted at least 6 months. Sixty-six patients were included in the study; 39 were treated with bisphosphonates (A), and 27 were drug-free (B). Presently, 24 group A and 13 group B patients have completed the 12-month observation period.

Results: In group A 53.8% (21) subjects had osteoporosis and 46.2% (18), osteopenia. Mean T-score L(2)-L(4) in group A at 1, 6, and 12 months were: (-)2.22 +/- 1.06; (-)2.07 +/- 1.25; (-)1.89 +/- 1.07, respectively. The T-score increase between 6 and 12 months was significant (P = 0.0014). The relative rise in BMD L(2)-L(4) between 1 and 12 months was 2.26%. In group B mean T-score L(2)-L(4) at 1, 6, and 12 months were: (-)0.26 +/- 1.34; (-)0.80 +/- 1.19; (-)1.2 +/- 1.59, respectively. The T-score decrease between 1 and 12 months in group B was significant (P = .0082). The 12-month relative decrease in femoral neck and trochanter BMD in group B was (-)2.1% and (-)2.75%, respectively.

Conclusion: Bisphosphonates are effective for prophylaxis of rapid bone loss early after renal transplantation.

MeSH terms

  • Absorptiometry, Photon
  • Alendronate / therapeutic use*
  • Bone Density / drug effects
  • Bone Density Conservation Agents / therapeutic use*
  • Bone Diseases, Metabolic / drug therapy*
  • Bone Resorption / prevention & control*
  • Etidronic Acid / analogs & derivatives*
  • Etidronic Acid / therapeutic use
  • Humans
  • Kidney Transplantation / adverse effects*
  • Organophosphonates / therapeutic use*
  • Osteoporosis / drug therapy*
  • Postoperative Complications / drug therapy
  • Postoperative Complications / prevention & control*
  • Risedronic Acid

Substances

  • Bone Density Conservation Agents
  • Organophosphonates
  • Risedronic Acid
  • Etidronic Acid
  • Alendronate